A phase I/II study of HLA-Matched mobilized peripheral blood hematopoetic stem cell transplantation for advanced mycosis fungoides/sezary using nonmyeloablative conditioning With Campath-1H [alemtuzumab]

Trial Profile

A phase I/II study of HLA-Matched mobilized peripheral blood hematopoetic stem cell transplantation for advanced mycosis fungoides/sezary using nonmyeloablative conditioning With Campath-1H [alemtuzumab]

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs Alemtuzumab (Primary) ; Ciclosporin; Cyclophosphamide; Fludarabine
  • Indications Graft-versus-host disease; Mycosis fungoides; Sezary syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Mar 2018 Planned End Date changed from 30 Dec 2018 to 1 Jul 2021.
    • 02 Mar 2018 Planned End Date changed from 30 Dec 2018 to 1 Jul 2021.
    • 02 Mar 2018 Planned primary completion date changed from 30 Dec 2018 to 1 Jul 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top